A Phase 3 interventional study of JZP-258 and Placebo Oral Solution in Idiopathic Hypersomnia, sponsored by Jazz Pharmaceuticals. Completed at 63 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-24.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 7th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
Takeda · Sites in United States, Australia, China and 2 more countries
Ages 18–71
University of Pittsburgh · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Canada
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in United States, Canada, Italy and 1 more country
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 82 across 40 interventional studies indexed under Idiopathic Hypersomnia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 3 studies filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Hypersomnia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT05837091Mayo ClinicLow Sodium Oxybate in Patients With Idiopathic Hypersomnia | 2027-01-29 |
Add all 5 to your calendar (.ics) → With an account.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JZP-258 at the stable dose and regimen for 2 weeks.
Drug: JZP-258
Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
Drug: Placebo Oral Solution
Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
Change in Epworth Sleepiness Scale (ESS) Score
The ESS is a 8-item self reported questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A positive mean change value indicates an increase in score from the end of the stable dose period and worsened daytime sleepiness. A higher ESS score (above 10) reflects a greater average sleep propensity in daily life (ASP) , or daytime sleepiness.
Time frame: Change from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period (DBRW) (2 Weeks)
Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)
The Patient Global Impression - Change (PGIc) scale was completed by the participant. The PGI-C scale rated the participant's condition at a specified time point on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The PGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a PGIc rating of 5, 6, or 7.
Time frame: At the end of the DBRW Period (2 Weeks)
Change in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS)
The IHSS is a 14-item self-reported questionnaire assessing the severity of IH symptoms of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. Total scores can range from 0 to 50, with higher scores indicating a greater severity or frequency of symptoms.
Time frame: Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)
Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc)
The CGIc scale is a 7-point Likert-type scale that rates the Investigator's impression of any change in the severity of the participant's condition at a specified time point. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The CGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a CGIc rating of 5, 6, or 7.
Time frame: At the end of the DBRW Period (2 Weeks)
Change in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10)
The FOSQ-10 is a short version of the original FOSQ-30 instrument, which is a disease specific quality of life questionnaire to determine functional status in adults. Measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these activities are improved by effective treatment. The questionnaire has a 4-point Likert response format (e.g., 1= extreme difficulty, 2= moderate difficulty, 3=a little difficulty, and 4 =no difficulty). FOSQ-10 total score is calculated by first taking the mean of the items for each subscale with more than 1 item completed and then taking the mean across the non-missing 5 subscales (General Productivity, Activity Level, Vigilance, Social Outcomes, Intimacy and Sexual Relationship) multiplied by 5. The score ranges from a minimum of 5 points to a maximum of 20 points, with higher scores indicating better functional status.
Time frame: Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)
The safety population is categorized according to the presence or absence of medications used to treat IH symptoms at the time of study baseline.
| Milestone | On Baseline IH Medication | Treatment Naive |
|---|---|---|
| Started | 88 | 66 |
| Completed | 57 | 38 |
| Not completed | 31 | 28 |
| Withdrew: Adverse event | 16 | 11 |
| Withdrew: Consent withdrawal by participant | 7 | 6 |
| Withdrew: Lack of efficacy | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Protocol deviation | 1 | 1 |
| Withdrew: Failure to meet randomization criteria | 1 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Milestone | On Baseline IH Medication | Treatment Naive |
|---|---|---|
| Started | 88 | 66 |
| Completed | 72 | 53 |
| Not completed | 16 | 13 |
| Withdrew: Adverse event | 11 | 8 |
| Withdrew: Consent withdrawal by participant | 2 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Milestone | On Baseline IH Medication | Treatment Naive |
|---|---|---|
| Started | 71 | 52 |
| Completed | 69 | 50 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Consent withdrawal by participant | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Milestone | On Baseline IH Medication | Treatment Naive |
|---|---|---|
| Started | 69 | 47 |
| Jzp-258 | 57 | 0 |
| Placebo | 0 | 59 |
| Completed | 67 | 46 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Failure to meet randomization criteria | 1 | 0 |
| Milestone | On Baseline IH Medication | Treatment Naive |
|---|---|---|
| Started | 65 | 41 |
| Completed | 57 | 38 |
| Not completed | 8 | 3 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Consent withdrawal by participant | 2 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
The ESS is a 8-item self reported questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A positive mean change value indicates an increase in score from the end of the stable dose period and worsened daytime sleepiness. A higher ESS score (above 10) reflects a greater average sleep propensity in daily life (ASP) , or daytime sleepiness.
| score on a scale | JZP-258 | Placebo |
|---|---|---|
| Change in Epworth Sleepiness Scale (ESS) Score | 0.7 ± 3.22 | 7.4 ± 5.16 |
The Patient Global Impression - Change (PGIc) scale was completed by the participant. The PGI-C scale rated the participant's condition at a specified time point on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The PGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a PGIc rating of 5, 6, or 7.
| participants | JZP-258 | Placebo |
|---|---|---|
| Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc) | 12 | 52 |
The IHSS is a 14-item self-reported questionnaire assessing the severity of IH symptoms of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. Total scores can range from 0 to 50, with higher scores indicating a greater severity or frequency of symptoms.
| score on a scale | JZP-258 | Placebo |
|---|---|---|
| Change in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS) | 0.0 (-8 to 24) | 14.0 (-2 to 38) |
The CGIc scale is a 7-point Likert-type scale that rates the Investigator's impression of any change in the severity of the participant's condition at a specified time point. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The CGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a CGIc rating of 5, 6, or 7.
| participants | JZP-258 | Placebo |
|---|---|---|
| Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc) | 12 | 52 |
The FOSQ-10 is a short version of the original FOSQ-30 instrument, which is a disease specific quality of life questionnaire to determine functional status in adults. Measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these activities are improved by effective treatment. The questionnaire has a 4-point Likert response format (e.g., 1= extreme difficulty, 2= moderate difficulty, 3=a little difficulty, and 4 =no difficulty). FOSQ-10 total score is calculated by first taking the mean of the items for each subscale with more than 1 item completed and then taking the mean across the non-missing 5 subscales (General Productivity, Activity Level, Vigilance, Social Outcomes, Intimacy and Sexual Relationship) multiplied by 5. The score ranges from a minimum of 5 points to a maximum of 20 points, with higher scores indicating better functional status.
| score on a scale | JZP-258 | Placebo |
|---|---|---|
| Change in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10) | -0.08 (-8.5 to 4.5) | -4.17 (-12.5 to 1.3) |
Collected over Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the time on or after the first dose of study drug, including adverse events that occurred until 30 days after the last dose date up to 42 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On Baseline IH Medication | 0/88 (0%) | 2/88 (2.3%) | 64/88 (72.7%) |
| Treatment Naive | 0/66 (0%) | 2/66 (3%) | 39/66 (59.1%) |
| JZP-058 | 0/154 (0%) | 4/154 (2.6%) | 97/154 (63%) |
| Placebo | 0/59 (0%) | 0/59 (0%) | 10/59 (16.9%) |
| Event | On Baseline IH Medication | Treatment Naive | JZP-058 | Placebo |
|---|---|---|---|---|
| PyelonephritisInfections and infestations | 0/88 | 1/66 | 1/154 | 0/59 |
| SyncopeNervous system disorders | 0/88 | 1/66 | 1/154 | 0/59 |
| NephrolithiasisRenal and urinary disorders | 0/88 | 1/66 | 1/154 | 0/59 |
| Non-cardiac chest painGeneral disorders | 1/88 | 0/66 | 1/154 | 0/59 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/88 | 0/66 | 1/154 | 0/59 |
| Event | On Baseline IH Medication | Treatment Naive | JZP-058 | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 21/88 | 13/66 | 34/154 | 1/59 |
| HeadacheNervous system disorders | 15/88 | 12/66 | 27/154 | 2/59 |
| VomitingGastrointestinal disorders | 15/88 | 3/66 | 17/154 | 2/59 |
| DizzinessNervous system disorders | 8/88 | 11/66 | 19/154 | 0/59 |
| InsomniaPsychiatric disorders | 13/88 | 4/66 | 11/154 | 6/59 |
| DiarrhoeaGastrointestinal disorders | 11/88 | 3/66 | 12/154 | 2/59 |
| AnxietyPsychiatric disorders | 10/88 | 8/66 | 17/154 | 1/59 |
| Decreased appetiteMetabolism and nutrition disorders | 7/88 | 7/66 | 14/154 | 0/59 |
| TremorNervous system disorders | 9/88 | 0/66 | 9/154 | 0/59 |
| Dry mouthGastrointestinal disorders | 8/88 | 2/66 | 10/154 | 0/59 |
| Age, Continuous(years) | On Baseline IH Medication | Treatment Naïve | Total |
|---|---|---|---|
| Mean | 41.0 ± 13.37 | 39.4 ± 14.25 | 40.3 ± 13.73 |
| Sex: Female, Male(Participants) | On Baseline IH Medication | Treatment Naïve | Total |
|---|---|---|---|
| Female | 65 | 40 | 105 |
| Male | 23 | 26 | 49 |
| Race (NIH/OMB)(Participants) | On Baseline IH Medication | Treatment Naïve | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 5 | 4 | 9 |
| White | 76 | 53 | 129 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 7 | 7 | 14 |
| Region of Enrollment(participants) | On Baseline IH Medication | Treatment Naïve | Total |
|---|---|---|---|
| North America | 69 | 35 | 104 |
| Europe | 19 | 31 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Jun 2020, 18 months.
Results were first posted in Nov 2021, 1 year 5 months after primary completion. A results delay was requested in Jun 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JZP258